Francesca Guana

Via Malta 3, BI
Biella, 13900, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Application of PathoChip to urine-derived nucleic acids for broad microbial profiling in men with suspected prostate cancer: setup of a methodological workflow and pilot feasibility study.

Application of PathoChip to urine-derived nucleic acids for broad microbial profiling in men with suspected prostate cancer: setup of a methodological workflow and pilot feasibility study.

Journal: The journal of liquid biopsy

Published: July 14, 2026

Integrating anamnestic and lifestyle data with sphingolipid levels for risk-based prostate cancer screening.

Integrating anamnestic and lifestyle data with sphingolipid levels for risk-based prostate cancer screening.

Journal: Journal of translational medicine

Published: May 21, 2025

Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab.

Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab.

Journal: Clinical and experimental medicine

Published: April 12, 2024

SOMAscan Proteomics Identifies Novel Plasma Proteins in Amyotrophic Lateral Sclerosis Patients.

SOMAscan Proteomics Identifies Novel Plasma Proteins in Amyotrophic Lateral Sclerosis Patients.

Journal: International journal of molecular sciences

Published: November 17, 2022

A Circulating Risk Score, Based on Combined Expression of Exo-miR-130a-3p and Fibrinopeptide A, as Predictive Biomarker of Relapse in Resectable Non-Small Cell Lung Cancer Patients.

A Circulating Risk Score, Based on Combined Expression of Exo-miR-130a-3p and Fibrinopeptide A, as Predictive Biomarker of Relapse in Resectable Non-Small Cell Lung Cancer Patients.

Journal: Cancers

Published: March 24, 2022

VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status.

VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status.

Journal: Journal of hematology & oncology

Published: August 04, 2021

Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma.

Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma.

Journal: Frontiers in immunology

Published: October 27, 2020

AKR1C3 is a biomarker and druggable target for oropharyngeal tumors.

AKR1C3 is a biomarker and druggable target for oropharyngeal tumors.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: October 21, 2020

Evaluation of Left Ventricular Volumes and Ejection Fraction from Gated Myocardial Perfusion SPECT Processed with "Myovation Evolution": Comparison of Three Automated Software Packages using Cardiac Magnetic Resonance as Reference.

Evaluation of Left Ventricular Volumes and Ejection Fraction from Gated Myocardial Perfusion SPECT Processed with "Myovation Evolution": Comparison of Three Automated Software Packages using Cardiac Magnetic Resonance as Reference.

Journal: Current radiopharmaceuticals

Published: April 28, 2020

Gene Expression Signature Predictive of Neuroendocrine Transformation in Prostate Adenocarcinoma.

Gene Expression Signature Predictive of Neuroendocrine Transformation in Prostate Adenocarcinoma.

Journal: International journal of molecular sciences

Published: December 24, 2019

Showing 1-10 of 10

Last Updated: 09/26/2026